This article is more than 5 years old. Information may no longer be current.

New indication for Medtronic glucose sensor may improve accuracy with artificial pancreas

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA recently approved a new indication for Medtronic’s Guardian Sensor 3 allowing the device to be worn on the upper arm, according to a company press release.

The new sensor position is meant to allow for more flexibility and improved accuracy with a mean absolute relative difference of 8.7% after typical calibration methods used with the MiniMed 670G system. The Guardian Sensor 3 is the only FDA-approved sensor for use with a hybrid closed-loop system, or “artificial pancreas,” to control automated insulin delivery.

“The performance of the Guardian Sensor 3 has been extremely impressive, and this new arm indication now offers added convenience and flexibility for my patients who like to have as many options as possible to address their personal needs,” Bruce Bode, MD, FACE, a specialist with Atlanta Diabetes Associated and a clinical associate professor at Emory University, said in the release. “These continued enhancements demonstrate a keen focus on the part of Medtronic to deliver a positive patient experience in addition to optimizing outcomes through technological advancements — that can prove to be just as meaningful for quality of life.”

The Guardian Sensor 3 is currently approved for use in people with type 1 diabetes at least 14 years in the United States for use with the MiniMed 670G system. The system features the SmartGuard algorithm which increases time in range with automatic basal insulin delivery based on real-time data.

“We are steadfast in our commitment to delivering both best-in-class clinical outcomes as well as best-in-class experiences for our customers,” Alejandro Galindo, president of the intensive management division within the diabetes group at Medtronic, said in the release. “We are inspired by the many voices in the diabetes community who continue to shape our offerings in a meaningful way as we work to address the wide spectrum of needs within the community. We are very pleased to offer this added flexibility for those who rely on our therapies for their diabetes management needs.”